Pathogenic mutations in SWI/SNF chromatin-remodeling complex members occur in 53 approximately 20% of cancers, but no targeted therapies that exploit a tumor's dependence on 54 SWI/SNF dysfunction have yet shown clinical impact. Small cell carcinoma of the ovary, 55 hypercalcemic type (SCCOHT) is a rare and aggressive form of ovarian cancer affecting young 56 women. It is characterized by mutational inactivation of SMARCA4 and epigenetic silencing of 57 SMARCA2, the mutually exclusive ATPases of the SWI/SNF complex. Here, we demonstrate 58 potency of the FDA-approved oncology drug, ponatinib, a receptor tyrosine kinase (RTK) 59 inhibitor whose targets include PDGFRs, FGFRs and EphAs, in SCCOHT cell and animal 60 models. This work suggests that ponatinib exploits SCCOHT's dependence on RTK signaling in 61 the context of SWI/SNF dysregulation and that ponatinib may be effective in SCCOHT 62 treatment. Preclinical identification of an effective, approved oncology drug holds promise for 63 rapidly improving outcomes for these young patients and warrants clinical investigation. 64
Purpose: Subunits of the SWI/SNF chromatin-remodeling complex are tumor suppressors 66 inactivated in ~20% of all cancers. Yet, few targeted treatments for SWI/SNF-mutant cancers 67 exist. Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare, aggressive 68 ovarian cancer in young women that is universally driven by loss of the SWI/SNF ATPase 69 subunits, SMARCA4 and SMARCA2. Given poor two-year survival rates for these women, a 70 great need exists for effective targeted therapies. 71
Experimental Design: To identify underlying therapeutic vulnerabilities in SCCOHT, we 72 conducted high-throughput siRNA and drug screens. Complementary proteomics approaches 73 comprehensively profiled kinases inhibited by ponatinib. Ponatinib was tested for efficacy in two 74
PDX models and one cell line xenograft model of SCCOHT. 75
Results: FGFRs and PDGFRs were overlapping hits between screens and the receptor tyrosine 76 kinase (RTK) family was enriched in the siRNA screen hits. Evaluation of eleven RTK inhibitors 77 in three SCCOHT cell lines identified ponatinib, an inhibitor of multiple RTKs, as the most 78 effective clinically approved agent. Proteomics approaches confirmed inhibition of known 79 targets of ponatinib and more than 20 non-canonical ponatinib targets. Ponatinib also delayed 80 tumor doubling time 4-fold in SCCOHT-1 xenografts and reducing final tumor volumes in two 81
Introduction 88
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a rare and aggressive 89 form of ovarian cancer, is diagnosed in women at a median age of 24 years (range: 14 months to 90 47 years) (1). Meta-analysis of 257 clinically annotated SCCOHT cases has shown a dismal two-91
year survival rate less than 35% and the most effective treatment regimen based on this 92 assessment is surgery followed by aggressive high dose chemotherapy, radiation, and stem cell 93 rescue (1,2). The poor response rates and extreme toxicity of this regimen necessitate 94 identification of effective, targeted treatments for these young patients. SCCOHTs are 95 characterized by inactivating germline and somatic mutations in the tumor suppressor SMARCA4 96 (also known as BRG1) resulting in concomitant protein loss in nearly all cases (3-8). These 97 SMARCA4 alterations occur amidst otherwise diploid SCCOHT genomes and very rare 98 secondary mutations in other cancer genes (4,8). SMARCA4 is one of two mutually exclusive 99
ATPase subunits of the SWI/SNF chromatin-remodeling complex that plays a central role in 100 regulation of transcriptional programs associated with differentiation. The alternative SWI/SNF 101 ATPase, SMARCA2 (also known as BRM), is also absent in SCCOHT due to epigenetic 102 silencing (3,7). Thus, these tumors are driven by a unique genotype that fuels broad 103 transcriptional dysregulation through SWI/SNF dysfunction. 104
Several other tumor types are also universally characterized by inactivation of SWI/SNF 105 complex members including thoracic sarcomas bearing SMARCA4 mutation and SMARCA2 loss 106 (9), rhabdoid tumors which are universally characterized by SMARCB1 (also known as SNF5) 107 mutations alongside SMARCA2 silencing and expression loss in 70% of cases (10,11), and renal 108 medullary cancers also characterized by SMARCB1 loss (12,13). Other cancers with a 109 significant proportion of SWI/SNF mutations include ovarian clear cell carcinomas and 7 endometrioid carcinomas (~50% and ~30% with ARID1A loss, respectively) (14, 15) in SCCOHT (20-22). We and others have also shown that investigational epigenetic agents such 119 as bromodomain and EZH2 inhibitors may hold promise for treatment of these cancers (23) (24) (25) . 120
Yet, despite the prevalence of pathogenic SWI/SNF mutations in cancer, no approved targeted 121 cancer drugs have yet shown activity in the setting of loss of these tumor suppressors. In order to 122 identify novel therapeutic vulnerabilities conferred by SWI/SNF dysfunction in SCCOHT with a 123 focus on identification of targeted FDA-approved oncology drugs, we performed high-124 throughput (HT) siRNA and drug screens in SCCOHT cell lines. We thereby identified 125 enrichment for dependence on receptor tyrosine kinase (RTK) signaling both via an abundance 126 of RTK hits in the siRNA screen as well as discovery of SCCOHT hypersensitivity to the RTK 127 Tumors were excised upon necropsy and either frozen or formalin-fixed/paraffin-embedded. 198
Results 202
High-throughput in vitro siRNA and drug screens prioritize ponatinib as an FDA-approved 203 oncology drug with potent activity in SCCOHT cell lines 204
In an effort to identify SCCOHT's therapeutic vulnerabilities, HT siRNA libraries were 205 used to test necessity of clinically actionable genes or growth of the SCCOHT cell line BIN67. 206
We transfected siRNAs targeting over 7,000 genes in both Druggable Genome (DGv3) and also 207 custom kinome (vKINv4) libraries. Hits were determined based on measurement of cell viability 208 reduction using CellTiter Glo measurements analyzed via a combination of redundant siRNA 209 activity score (RSA) p-value ranking with ranking by mean signal intensity and utilizing a p-210 value cutoff of 0.05 (see Supplemental Materials and Methods for further detail). Of 246 genes 211 from the DGv3 library and 81 genes from the vKINv4 library identified as hits based on these 212 criteria, 109 were also validated through independent confirmation that two of four siRNAs 213 inhibited viability by >50% (See Supplemental Materials and Methods and Supplemental Table  214 1). The ReactomeFI Cytoscape plugin was then used to identify pathways enriched in these 215 validated hits ( as demonstrated by the PDGFR signaling pathway ( Figure 1A ). All kinase hits from the two 220 siRNA screens were also plotted on a kinome tree to identify key kinase families on which 221 SCCOHT cells are reliant for growth (Supplemental Figure 1 ). Tyrosine kinases, particularly 222
RTKs, were most strongly identified amongst the kinase hits. A second pathway analysis 223 method, ClueGO, was used to visualize the biological concepts represented in the top hits 224 (Supplemental Figure 2 ). This method also identified interaction between RTKs in top hits 225 through functions in cancer signaling, regulation of actin cytoskeleton, and cell adhesion. 226
Together, these data suggest a broad dependency of SCCOHT cells on RTK signaling networks. 227
In an effort to identify novel candidate drugs for targeted treatment of SCCOHT in an 228 unbiased manner, high-throughput (HT) drug screens were performed in BIN67 cells using two 229 libraries of ~2,300 small molecules. All of these compounds are pharmacologically active with 230 well-annotated drug targets from a wide breadth of signaling pathways, and over half of these are 231 approved for at least one clinical indication. Given that SCCOHT's cell of origin remains 232 unknown and, further, that isogenic model systems restoring SMARCA4 expression in SCCOHT 233 result in senescence, we did not utilize a normal or isogenic comparator to identify selective hits. 234
Instead, we chose to identify compounds active in BIN67 SCCOHT cells and to filter out broadly 235 cytotoxic drugs that also showed effect in HepG2 cells. Hits were then defined as those agents 236 that reduced viability of BIN67 cells by >50% relative to HepG2 according to CellTiter Glo 237 measurements at 72 hours post-treatment (see Supplemental Materials and Methods for further 238 detail). From these screens, 64 compounds reduced growth of BIN67 but not HepG2 cells 239 Table 2 ). Of these hits, 51 were next validated in 12-point drug dose-response 240 (DDR) format in the SCCOHT cell lines BIN67, SCCOHT-1, and COV434 as well as a 241 SMARCA4-wild-type human granulosa cell line SVOG3e and HepG2 cells. Of the 51 242 compounds tested, 42 were confirmed to have IC 50 values >10-fold lower in BIN67 cells than 243 Table 3 ). Generally IC 50 values from BIN67 cells were similar to 244 those in SCCOHT-1 and COV434, as well as for SVOG3e. The 42 validated drug hits were 245 annotated based on their reported targets in preclinical literature and vendor database and visualized using Cytoscape ( Figure 1B ). Network cliques with the highest number of 248 connected compounds were associated with microtubule targeting or DNA damage induction. 249
HepG2 cells (Supplemental
These network cliques are representative of current standard treatments for SCCOHT, which 250 include vinblastine, doxorubicin, and etoposide (2). While the original Prestwick chemical 251 library did not contain any annotated RTKi, the LOPAC library included 27 RTKi, of which nine 252 were EGFR inhibitors, two were IGF-1R inhibitors, two were FGFR inhibitors, one was a 253 PDGFR inhibitor, and the remaining targeted miscellaneous or unannotated RTKs. Two of these 254
RTKi were identified as hits in the validation set: PD-161570 and Tyrphostin A9. While these 255 agents demonstrate some selectivity for FGFR1 and PDGFRs, respectively, they are not selective 256 for these targets alone, and are known to broadly target multiple RTKs. 257
To follow up on evidence of RTK dependence in the siRNA and chemical screens, we 258 assessed sensitivity of BIN67 and SCCOHT-1 to 11 RTKi. We selected a subset of RTKi, 259 particularly those targeting FGFRs and PDGFRs. Drug Dose Response (DDR) assays were 260 performed (Figure 2A following treatment with IC 50 ponatinib ( Figure 3B) . 280 281
Functional characterization of ponatinib action reveals broad kinase targeting in SCCOHT cells 282
Since ponatinib is a broad RTKi, several orthogonal approaches were undertaken to 283 identify kinases inhibited by ponatinib in SCCOHT cells. First, RTK profiler arrays were 284 employed to screen for top RTKs inhibited by ponatinib treatment in BIN67 and SCCOHT-1. 285
This assay is a membrane-based sandwich immunoassay that captures key RTKs and detects 286 differential pan-tyrosine phosphorylation in cell lysates across conditions. The quantitation of 287 these arrays is shown in Figure 4A . Of the known ponatinib targets (highlighted in yellow), 288
PDGFRα phosphorylation was both detected at a high level relative to other RTKs and also 289 strongly inhibited by ponatinib in BIN67 cells only, but not in SCCOHT-1 cells. This 290 discordance between BIN67 and SCCOHT-1 would suggest that ponatinib inhibits unidentified 291 kinases in SCCOHT cells to affect cell growth. Among previously unreported targets of 292 ponatinib, phosphorylation of EGFR in BIN67 and SCCOHT-1 cells was greatly inhibited by 293 ponatinib, which represented the only common candidate between the two cell lines. Other RTKs 294 strongly inhibited by ponatinib treatment in BIN67 cells alone include RYK, CSF1R, ALK, and 295 TEK ( Figure 4A) . 296
Given the divergent results of the RTK array assay between ponatinib sensitivity in 297 SCCOHT-1 and BIN67, two additional proteomic approaches (MIB-MS and ABPP) were 298 undertaken to more fully characterize functional inhibition of kinases by ponatinib. Multiplexed 299 kinase inhibitor bead-mass spectrometry (MIB-MS) uses beads to pull down kinases from a cell 300 lysate in the presence or absence of an inhibitor such as ponatinib (35, 36) . Binding of ponatinib 301 to the kinase inhibits kinase binding to MIBs. Therefore, peptides corresponding to kinase targets 302 are lost in the subsequent mass spectrometry analyses and thereby considered hits. Due to 303 ponatinib hypersensitivity in SCCOHT-1 cells, this line was tested using MIB-MS to identify 304 additional candidates for ponatinib targeting (full data in Supplemental Table 4 ). Kinase hits 305 from most of the major kinase families were identified in SCCOHT-1 by this approach (Figure  306 4B). Kinases were considered targets in this experiment if, in the vehicle control, they were over-307 expressed (19 kinases) or uniquely detected (24 kinases) ( Figure 4B ). FGFR1, FGFR2, and Src 308 are known ponatinib targets and were among the differentially expressed genes. These kinases 309 similarly displayed reduced phosphorylation in the RTK array, but only at a high dose 310
comparable to that used for the MIB-MS analysis, suggesting that other kinases might be more 311 strongly inhibited by ponatinib at the relevant dose for cell death. Of the RTKs highly expressed 312 in SCCOHT tumors ( Figure 3A) , EphA5 was also identified as a target of ponatinib in the MIB-operates in SCCOHT, Activity-Based Protein Profiling (ABPP), uses chemical probes that 316 covalently bind to the ATP-binding pocket of kinases and therefore can tag kinases with 317 accessible and conformationally active ATP-binding pocket in a protein lysate prior to mass 318 spectrometry (full data in Supplemental Tables 5 and 6) (37). The same cutoff parameters 319 described above for MIB-MS were used for this dataset to determine unique and differentially 320 expressed active kinases. In SCCOHT-1 cells, we identified 13 differentially expressed kinases 321 and 4 unique kinases in the vehicle control treated cells ( Figure 4C ). Only seven differentially 322 expressed kinases in BIN67 cells were identified ( Figure 4C ). Two overlapping kinases were 323 identified in both BIN67 and SCCOHT-1 cells: tyrosine kinase EphA7 and STE-family kinase 324 LOK ( Figure 4C ). Interestingly, no RTK was significantly altered with ponatinib treatment in 325 either cell line, which might represent a bias of this assay due to exclusion of active-site peptides 326 via complementarity to other RTKs. Generally, tyrosine kinases and STE kinases were well-327 represented in both cell lines. 328
329

Ponatinib is effective in animal models of SCCOHT 330
To determine ponatinib's promise as a potential therapy, we tested its efficacy in animal 331 xenograft models of SCCOHT. Mice bearing subcutaneous SCCOHT-1 xenograft tumors 332 demonstrated an initial inhibition of tumor growth following ponatinib treatment, delaying tumor 333 progression ( Figure 5A ). Tumor doubling times from 200 to 400mm 3 in each group were 334 1.88±0.64 days in vehicle treated mice and 7.38±1.06 days in ponatinib treated mice (p-value < 335 0.0001). Treatment of SCCOHT-1 tumor bearing mice with ponatinib similarly improved 336 median survival by 44% ( Figure 5B ). To further assess the efficacy of ponatinib in patient-derived tumor models, we used two SCCOHT patient-derived xenograft (PDX) models: PDX-338 465 and PDX-040. After 30 days of treatment, tumor growth rate was slowed in both PDX 339 models, with statistically significant 58.6% and 42.5% decreases in tumor size relative to vehicle 340 treatment in PDX-465 and -040, respectively ( Figures 5C and 5D) . MRTs and SCCOHTs, but have not yet been approved for these indications. The SWI/SNF 359 complex itself has also been identified as the major target of bromodomain inhibitors through 360 direct interaction with bromodomain-containing SWI/SNF ATPases SMARCA2 and SMARCA4 361 (43). This is a particularly attractive target in some SMARCA4-deficient cancers in which 362 residual SMARCA2 compensates in the absence of SMARCA4 as the functional SWI/SNF 363 ATPase (44). Such an approach has been shown to be ineffective in SCCOHT, however, where 364 expression of both SWI/SNF ATPases has been lost (3). 365
The effects of PRC2 dependence on tumor suppressor silencing in SWI/SNF-mutant 366 cancers are well-studied. However, little is yet known about the effects of SWI/SNF dysfunction 367 on the overexpression of oncogenes such as RTKs, which might cause a tumor to develop unique 368 and targetable dependencies. Here, we show data supporting that targeting RTK activation in 369 tumors driven by epigenetic defects may provide clinical benefit. Using HT siRNA and drug 370 screens, our work has charted novel therapeutic vulnerabilities in SCCOHT cells. These studies 371 have not only confirmed in vitro sensitivity to cytotoxic drug classes already utilized in 372 SCCOHT treatment (e.g. tubulin inhibitors and DNA damaging agents), but they have also 373 pinpointed novel drug classes, such as cardiac glycosides, not previously implicated in treatment 374 of SWI/SNF-mutant cancers. Overall, these data converge on identification of hypersensitivity to 375 the FDA-approved multi-kinase inhibitor ponatinib and thereby emphasize the importance of 376 RTK signaling in these epigenetically dysregulated tumors. 377
We generally observed a striking similarity in drug sensitivity across the SCCOHT cell 378 lines and SVOG3e. While this observation strengthens the case for the sensitivity of SCCOHT 379 tumors to these agents, the similar sensitivity of SWI/SNF-intact SVOG3e cells indicates that 380 most of these agents do not selectively target SWI/SNF-mutant cells. The cell of origin of 381 expand cell models for each agent to better understand the relationship between cell lineage and 384 drug response. Interestingly, previous reports have shown expression of PDGFRs and c-kit, 385 known ponatinib targets, in granulosa cell tumors (46), suggesting convergent singaling 386 dependencies that may account for sensitivity to this drug in SCCOHT and SVOG3e cell lines. 387
Additional work is required to more completely characterize vulnerability of cancers with 388 SWI/SNF loss to the agents identified in this screen. 389
In examining overlap between the 42 hits in the drug screen and the 109 hits in the 390 siRNA screen, RTKs were the primary point of intersection. In addition to the overlap seen 391 within our HT screens, previous work has demonstrated sensitivity of SWI/SNF-mutant MRTs to 392 ponatinib (30). Mechanistically, our work supports data reported in SMARCB1-mutant MRTs, in 393 which loss of the core SWI/SNF subunit SMARCB1 results in elevated FGFR or PDGFR 394 expression (26,30). We similarly observed sensitivity of SCCOHT cell lines to ponatinib, a broad 395
RTKi. Multiple methods were integrated in an attempt to functionally identify a common target 396 of ponatinib responsible for efficacy of this drug in SCCOHT. Criteria considered included: 1) 397 expression in SCCOHT primary tumors, 2) requirement of expression for cell growth, and 3) 398 functional inhibition in the presence of ponatinib. Using these criteria, however, no common 399 target was identified, both between the extensive methods described here and the two SCCOHT 400 cell lines. Furthermore, the sensitivity of SCCOHT cells to other RTKi is inversely related to the 401 specificity of the RTKi to its intended target. Together, this evidence suggests general reliance of 402 SCCOHT on multiple kinases such that a broad kinase inhibitor such as ponatinib is effective. 403
When taken in combination with similar findings in MRTs (26,27,30) and the sensitivity 404 observed in other SWI/SNF mutant lung cancer cell lines reported here, we believe drug 405 sensitivity findings in the SCCOHT and MRT models might be more broadly applicable to a 20 larger set of "SWI/SNF-omas", or cancers with mutations in the SWI/SNF complex. This group 407 accounts for up to 20% of all cancers, and therefore has potential for broader translational 408 relevance. Our work also demonstrates the efficacy of ponatinib in SCCOHT preclinical animal 409 models. Ponatinib is a clinically approved agent used in the treatment of leukemias, and is being 410 
